CN101687919A - 治疗rsv感染和相关病症的方法 - Google Patents

治疗rsv感染和相关病症的方法 Download PDF

Info

Publication number
CN101687919A
CN101687919A CN200880022270A CN200880022270A CN101687919A CN 101687919 A CN101687919 A CN 101687919A CN 200880022270 A CN200880022270 A CN 200880022270A CN 200880022270 A CN200880022270 A CN 200880022270A CN 101687919 A CN101687919 A CN 101687919A
Authority
CN
China
Prior art keywords
rsv
antibody
amino acid
seq
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880022270A
Other languages
English (en)
Chinese (zh)
Inventor
S·克里希南
J·叙齐
P·基纳
G·洛松斯
H·吴
W·达拉夸
B·里克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN101687919A publication Critical patent/CN101687919A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880022270A 2007-06-26 2008-06-25 治疗rsv感染和相关病症的方法 Pending CN101687919A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US94627107P 2007-06-26 2007-06-26
US60/946,271 2007-06-26
US95326007P 2007-08-01 2007-08-01
US60/953,260 2007-08-01
US5492708P 2008-05-21 2008-05-21
US61/054,927 2008-05-21
PCT/US2008/068155 WO2009003019A1 (en) 2007-06-26 2008-06-25 Methods of treating rsv infections and related conditions

Publications (1)

Publication Number Publication Date
CN101687919A true CN101687919A (zh) 2010-03-31

Family

ID=40186020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880022270A Pending CN101687919A (zh) 2007-06-26 2008-06-25 治疗rsv感染和相关病症的方法

Country Status (8)

Country Link
US (1) US20110008329A1 (https=)
EP (1) EP2069400A4 (https=)
JP (1) JP2010531890A (https=)
KR (1) KR20100049568A (https=)
CN (1) CN101687919A (https=)
AU (1) AU2008268362A1 (https=)
CA (1) CA2688667A1 (https=)
WO (1) WO2009003019A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103048450A (zh) * 2011-10-13 2013-04-17 上海药明康德新药开发有限公司 高通量的rsv蛋白含量的定量检测法及其检测试剂盒
CN103097412A (zh) * 2010-07-09 2013-05-08 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
CN105916520A (zh) * 2014-01-15 2016-08-31 米迪缪尼有限公司 Rsv特异性抗体及其功能部分
CN108368556A (zh) * 2015-07-31 2018-08-03 智利天主教教皇大学 Il-3、il-33和il-12p40用于表征由合胞呼吸道病毒引起的呼吸系统感染的用途
CN115038721A (zh) * 2020-01-29 2022-09-09 高丽大学校产学协力团 pH敏感性Fc变体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
CN104119438A (zh) * 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2013165690A1 (en) * 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CN103204943B (zh) * 2013-03-20 2014-07-23 中国科学院武汉病毒研究所 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途
JP2017512208A (ja) * 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
US20210347885A1 (en) * 2018-09-21 2021-11-11 The University Of North Carolina At Chapel Hill Synthetic binding agents for limiting permeation through mucus
WO2021202463A1 (en) * 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP1893647A2 (en) * 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097412A (zh) * 2010-07-09 2013-05-08 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
CN103097412B (zh) * 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
CN103048450A (zh) * 2011-10-13 2013-04-17 上海药明康德新药开发有限公司 高通量的rsv蛋白含量的定量检测法及其检测试剂盒
CN105916520A (zh) * 2014-01-15 2016-08-31 米迪缪尼有限公司 Rsv特异性抗体及其功能部分
CN108368556A (zh) * 2015-07-31 2018-08-03 智利天主教教皇大学 Il-3、il-33和il-12p40用于表征由合胞呼吸道病毒引起的呼吸系统感染的用途
CN108368556B (zh) * 2015-07-31 2021-06-22 智利天主教教皇大学 Il-3、il-33和il-12p40用于表征由合胞呼吸道病毒引起的呼吸系统感染的用途
CN115038721A (zh) * 2020-01-29 2022-09-09 高丽大学校产学协力团 pH敏感性Fc变体

Also Published As

Publication number Publication date
KR20100049568A (ko) 2010-05-12
AU2008268362A1 (en) 2008-12-31
CA2688667A1 (en) 2008-12-31
US20110008329A1 (en) 2011-01-13
EP2069400A4 (en) 2012-03-07
JP2010531890A (ja) 2010-09-30
EP2069400A1 (en) 2009-06-17
WO2009003019A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CN101687919A (zh) 治疗rsv感染和相关病症的方法
JP6407187B2 (ja) 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US20100098708A1 (en) Methods of preventing and treating rsv infections and related conditions
US7229619B1 (en) Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2292663A2 (en) Antagonistic human light-specific human monoclonal antibodies
JP4976376B2 (ja) 哺乳動物メタニューモウイルスに対する抗体
CN102656189A (zh) 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
JP2008546805A (ja) 最適な凝集および断片化プロフィールを有する抗体製剤
JP2004534513A (ja) 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
US9499590B2 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20120263715A1 (en) Topical Methods Of Treating RSV Infections And Related Conditions
AU2012202860B2 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
HK1142914A (en) Methods of treating rsv infections and related conditions
CN101273061A (zh) 具有优化的聚集和片段化特性的抗体制剂
AU2012200987A1 (en) Methods of preventing and treating RSV infections and related conditions
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142914

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100331

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142914

Country of ref document: HK